Pipeline
ABL101
HomePipelineABL101
-
- Pipeline
- ABL101
-
- Program Target
- BCMAx4-1BB
-
- Disease Indication
- Hematologic Cancer
-
- Development Stage
- IND enabling study
- Summary
- A novel T-cell engaging bispecific antibody, ABL101 demonstrates a robust anti-tumor effect via BCMA mediated 4-1BB activation in tumor microenvironments (TME). ABL101 only activates 4-1BB signaling pathways in the presence of BCMA expressing cancer cells, minimizing the probability of hepatotoxicity in healthy tissues. ABL101 inhibits tumor growth and, by retaining immunological memory, induces a prolonged anti-tumor effect.
Structure and Mechanism of Action
BCMA Dependent 4-1BB Activation
ABL101 activates 4-1BB signaling only in the presence of tumor cells In a BCMA expression-dependent manner
